Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 28.56
OGXI's Cash to Debt is ranked lower than
51% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 42.60 vs. OGXI: 28.56 )
Ranked among companies with meaningful Cash to Debt only.
OGXI' s Cash to Debt Range Over the Past 10 Years
Min: 0.66  Med: 38.09 Max: No Debt
Current: 28.56
Equity to Asset 0.67
OGXI's Equity to Asset is ranked higher than
50% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. OGXI: 0.67 )
Ranked among companies with meaningful Equity to Asset only.
OGXI' s Equity to Asset Range Over the Past 10 Years
Min: 0.3  Med: 0.62 Max: 0.95
Current: 0.67
0.3
0.95
Interest Coverage N/A
OGXI's Interest Coverage is ranked lower than
54% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OGXI: N/A )
Ranked among companies with meaningful Interest Coverage only.
OGXI' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: N/A Max: No Debt
Current: N/A
N/A
No Debt
F-Score: 3
Z-Score: -5.58
M-Score: -0.64
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -106.51
OGXI's Operating margin (%) is ranked lower than
53% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. OGXI: -106.51 )
Ranked among companies with meaningful Operating margin (%) only.
OGXI' s Operating margin (%) Range Over the Past 10 Years
Min: -405.51  Med: -117.39 Max: -10.11
Current: -106.51
-405.51
-10.11
Net-margin (%) -94.65
OGXI's Net-margin (%) is ranked lower than
52% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -81.84 vs. OGXI: -94.65 )
Ranked among companies with meaningful Net-margin (%) only.
OGXI' s Net-margin (%) Range Over the Past 10 Years
Min: -266.98  Med: -104.99 Max: -21.44
Current: -94.65
-266.98
-21.44
ROE (%) -50.55
OGXI's ROE (%) is ranked lower than
62% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: -31.92 vs. OGXI: -50.55 )
Ranked among companies with meaningful ROE (%) only.
OGXI' s ROE (%) Range Over the Past 10 Years
Min: -77.65  Med: -41.29 Max: -28.99
Current: -50.55
-77.65
-28.99
ROA (%) -30.03
OGXI's ROA (%) is ranked lower than
52% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. OGXI: -30.03 )
Ranked among companies with meaningful ROA (%) only.
OGXI' s ROA (%) Range Over the Past 10 Years
Min: -52.42  Med: -25.55 Max: -13.07
Current: -30.03
-52.42
-13.07
ROC (Joel Greenblatt) (%) -3846.03
OGXI's ROC (Joel Greenblatt) (%) is ranked lower than
77% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -387.57 vs. OGXI: -3846.03 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OGXI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -18547.17  Med: -4248.24 Max: -230.97
Current: -3846.03
-18547.17
-230.97
Revenue Growth (3Y)(%) 38.40
OGXI's Revenue Growth (3Y)(%) is ranked higher than
87% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 3.70 vs. OGXI: 38.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OGXI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -48.7 Max: 637
Current: 38.4
0
637
EBITDA Growth (3Y)(%) -10.90
OGXI's EBITDA Growth (3Y)(%) is ranked lower than
63% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. OGXI: -10.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OGXI' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -74.3  Med: -4.2 Max: 104.5
Current: -10.9
-74.3
104.5
EPS Growth (3Y)(%) -1.30
OGXI's EPS Growth (3Y)(%) is ranked higher than
53% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. OGXI: -1.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OGXI' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -73.5  Med: -0.65 Max: 87.9
Current: -1.3
-73.5
87.9
» OGXI's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-12)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

OGXI Guru Trades in Q3 2015

Jim Simons 717,400 sh (-14.29%)
» More
Q4 2015

OGXI Guru Trades in Q4 2015

Jim Simons 757,000 sh (+5.52%)
» More
Q1 2016

OGXI Guru Trades in Q1 2016

Jim Simons 806,700 sh (+6.57%)
» More
Q2 2016

OGXI Guru Trades in Q2 2016

Jim Simons 876,100 sh (+8.60%)
» More
» Details

Insider Trades

Latest Guru Trades with OGXI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:PRGB, OTCPK:MBXBF, OTCPK:BCTXF, NAS:MATN, OTCBB:RGBP, NAS:CSBR, OTCPK:ENZN, OTCPK:CVALF, AMEX:APHB, NAS:BSTG, OTCPK:ETST, NAS:WINT, NAS:EYEG, NAS:STEM, AMEX:IMUC, NAS:RXII, OTCPK:GBLX, OTCPK:ATBPF, OTCPK:THCBF, OTCPK:OPNT » details
Traded in other countries:SP4A.Germany,
OncoGenex Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the development & commercialization of therapies that address treatment resistance in cancer patients. It has three product candidates including custirsen, apatorsen & OGX-225.

OncoGenex Pharmaceuticals Inc was incorporated in California in October 1991 and reorganized as a Delaware corporation in March 1995. The Company is a biopharmaceutical company. The Company is engaged in the development and commercialization of new therapies that address treatment resistance in cancer patients. The Company has developed a pipeline of late-stage product candidates that are designed to block the production of specific proteins that promote treatment resistance in cancer. The Company has three product candidates in pipeline including custirsen, apatorsen and OGX-225, each of which has a distinct mechanism of action and represents a opportunity for cancer drug development. Of the product candidates in pipeline, custirsen and apatorsen are clinical-stage assets being evaluated in two phase 3 studies and five phase 2 studies. The Company's product candidate's custirsen, apatorsen and OGX-225 focus on mechanisms of treatment resistance in cancer patients and are designed to block the production of specific proteins that promote treatment resistance and survival of tumor cells and are over-produced in response to a variety of cancer treatments. Custirsen is currently being evaluated in two phase 3 trials; one in patients with prostate cancer and one in patients with non-small cell lung cancer, or NSCLC. Custirsen is designed to inhibit the production of clusterin, a protein that promotes survival of cancer cells when overexpressed in a variety of tumors. Apatorsen is a product candidate designed to inhibit production of heat shock protein 27, or Hsp27, a cell-survival protein expressed in many types of cancers including bladder, non-small cell lung, pancreatic, prostate and breast cancers. OGX-225 is a product candidate designed to inhibit the production of Insulin Growth Factor Binding Proteins -2 and -5 (IGFBP-2, IGFBP-5), two proteins that affect the growth of cancer cells when overexpressed. The Company faces competition from pharmaceutical, biopharmaceutical and biotechnology companies that are researching and marketing products designed to address cancer indications. The Company owns trademarks registered in the United States, namely word marks ONCOGENEX, ORCA, Spruce, and Rainier, and design marks ORCA, Cedar, Pacific, Borealis-1, Borealis-2, and the helical totem element that accompanies the clinical trial trademarked identifiers. The research, testing, manufacturing, labeling, approval, selling, marketing and distribution of drug products are subject to extensive regulation by the FDA and non-U.S. regulatory authorities, which regulations differ from country to country.

Ratios

vs
industry
vs
history
P/B 0.61
OGXI's P/B is ranked higher than
97% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: 3.67 vs. OGXI: 0.61 )
Ranked among companies with meaningful P/B only.
OGXI' s P/B Range Over the Past 10 Years
Min: 0.3  Med: 2.76 Max: 9
Current: 0.61
0.3
9
P/S 0.90
OGXI's P/S is ranked higher than
95% of the 681 Companies
in the Global Biotechnology industry.

( Industry Median: 11.30 vs. OGXI: 0.90 )
Ranked among companies with meaningful P/S only.
OGXI' s P/S Range Over the Past 10 Years
Min: 0.03  Med: 3.85 Max: 47.89
Current: 0.9
0.03
47.89
EV-to-EBIT 1.11
OGXI's EV-to-EBIT is ranked higher than
89% of the 238 Companies
in the Global Biotechnology industry.

( Industry Median: 23.94 vs. OGXI: 1.11 )
Ranked among companies with meaningful EV-to-EBIT only.
OGXI' s EV-to-EBIT Range Over the Past 10 Years
Min: -49.9  Med: -2.6 Max: 2.2
Current: 1.11
-49.9
2.2
EV-to-EBITDA 1.13
OGXI's EV-to-EBITDA is ranked higher than
90% of the 259 Companies
in the Global Biotechnology industry.

( Industry Median: 19.79 vs. OGXI: 1.13 )
Ranked among companies with meaningful EV-to-EBITDA only.
OGXI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -51  Med: -2.6 Max: 2.3
Current: 1.13
-51
2.3
Current Ratio 2.98
OGXI's Current Ratio is ranked lower than
63% of the 918 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. OGXI: 2.98 )
Ranked among companies with meaningful Current Ratio only.
OGXI' s Current Ratio Range Over the Past 10 Years
Min: 1.43  Med: 3.56 Max: 18.91
Current: 2.98
1.43
18.91
Quick Ratio 2.98
OGXI's Quick Ratio is ranked lower than
60% of the 918 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. OGXI: 2.98 )
Ranked among companies with meaningful Quick Ratio only.
OGXI' s Quick Ratio Range Over the Past 10 Years
Min: 1.43  Med: 3.56 Max: 18.91
Current: 2.98
1.43
18.91
Days Sales Outstanding 0.96
OGXI's Days Sales Outstanding is ranked higher than
98% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 61.43 vs. OGXI: 0.96 )
Ranked among companies with meaningful Days Sales Outstanding only.
OGXI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.96  Med: 53.93 Max: 312.07
Current: 0.96
0.96
312.07

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -32.40
OGXI's 3-Year Average Share Buyback Ratio is ranked lower than
78% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: -11.50 vs. OGXI: -32.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OGXI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -67.6  Med: -22.95 Max: -2.1
Current: -32.4
-67.6
-2.1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.66
OGXI's Price/Net Cash is ranked higher than
99% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 5.78 vs. OGXI: 0.66 )
Ranked among companies with meaningful Price/Net Cash only.
OGXI' s Price/Net Cash Range Over the Past 10 Years
Min: 0.59  Med: 3.77 Max: 46.55
Current: 0.66
0.59
46.55
Price/Net Current Asset Value 0.63
OGXI's Price/Net Current Asset Value is ranked higher than
99% of the 618 Companies
in the Global Biotechnology industry.

( Industry Median: 5.45 vs. OGXI: 0.63 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OGXI' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.49  Med: 3.69 Max: 37.72
Current: 0.63
0.49
37.72
Price/Tangible Book 0.61
OGXI's Price/Tangible Book is ranked higher than
98% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: 4.38 vs. OGXI: 0.61 )
Ranked among companies with meaningful Price/Tangible Book only.
OGXI' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.47  Med: 3.6 Max: 30.82
Current: 0.61
0.47
30.82
Price/Median PS Value 0.23
OGXI's Price/Median PS Value is ranked higher than
91% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. OGXI: 0.23 )
Ranked among companies with meaningful Price/Median PS Value only.
OGXI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.01  Med: 2.31 Max: 703.38
Current: 0.23
0.01
703.38
Earnings Yield (Greenblatt) (%) 89.61
OGXI's Earnings Yield (Greenblatt) (%) is ranked higher than
97% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.90 vs. OGXI: 89.61 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OGXI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 45.6  Med: 120 Max: 116330.9
Current: 89.61
45.6
116330.9

More Statistics

Revenue (TTM) (Mil) $17.82
EPS (TTM) $ -0.55
Beta1.87
Short Percentage of Float2.00%
52-Week Range $0.46 - 3.38
Shares Outstanding (Mil)30.01

Analyst Estimate

Dec16
Revenue (Mil $)
EPS ($) -1.99
EPS w/o NRI ($) -1.99
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for OGXI

Headlines

Articles On GuruFocus.com
George Soros Had A Mixed Day On The Market Oct 30 2014 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES (OGXI) President and CEO Scott Daniel Cormack sells 1 Jan 06 2011 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES (OGXI) President and CEO Scott Daniel Cormack sells 5 Dec 03 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES (OGXI) President and CEO Scott Daniel Cormack sells 5 Nov 17 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES (OGXI) President and CEO Scott Daniel Cormack sells 5 Nov 02 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q) Aug 05 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q/A) May 10 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q) May 06 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q) Nov 05 2009 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q) Aug 06 2009 

More From Other Websites
ONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... Aug 22 2016
Biotech Stock Roundup: Vertex Slips on Study Halt, Aurinia Plunges on Lupus Data Aug 17 2016
OncoGenex Down on Poor Phase III Data on Lead Cancer Drug Aug 17 2016
ONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 16 2016
OncoGenex Announces Results from the Phase 3 AFFINITY Trial of Custirsen in Men with Metastatic... Aug 16 2016
OncoGenex Announces Results from the Phase 3 AFFINITY Trial of Custirsen in Men with Metastatic... Aug 16 2016
OncoGenex Announces Results from the Phase 3 AFFINITY Trial of Custirsen in Men with Metastatic... Aug 16 2016
ONCOGENEX PHARMACEUTICALS, INC. Financials Aug 13 2016
Edited Transcript of OGXI earnings conference call or presentation 4-Aug-16 8:30pm GMT Aug 06 2016
ONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 04 2016
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2016 Aug 04 2016
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2016 Aug 04 2016
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2016 Aug 04 2016
Q2 2016 OncoGenex Pharmaceuticals Inc Earnings Release - After Market Close Aug 04 2016
ETF’s with exposure to OncoGenex Pharmaceuticals, Inc. : July 22, 2016 Jul 22 2016
OncoGenex to Report Second Quarter 2016 Financial Results on August 4, 2016 Jul 21 2016
OncoGenex to Report Second Quarter 2016 Financial Results on August 4, 2016 Jul 21 2016
ETF’s with exposure to OncoGenex Pharmaceuticals, Inc. : June 30, 2016 Jun 30 2016
Forget Valeant, Invest in These Attractive Drug Stocks Instead Jun 28 2016
ONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events Jun 20 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)